Proximal tubulopathy-diabetes mellitus-cerebellar ataxia syndrome

1. Disease Information

Overview: Proximal tubulopathy-diabetes mellitus-cerebellar ataxia syndrome is a multisystem mitochondrial disorder presenting in infancy with a severe proximal renal tubulopathy (Fanconi-type), followed during childhood by progressive development of skin pigmentary changes, mitochondrial myopathy (ragged-red fibers), cerebellar ataxia, sensorineural hearing loss, pigmentary retinopathy/blindness, osteoporosis, and diabetes mellitus. It is caused by a maternally inherited, heteroplasmic partial duplication of mitochondrial DNA, and mitochondrial respiratory chain analysis has demonstrated complex III (ubiquinol-cytochrome c reductase) deficiency in affected tissue (skeletal muscle and lymphocytes) [PMID:1531167].

Key identifiers: - OMIM: #560000 — "RENAL TUBULOPATHY, DIABETES MELLITUS, AND CEREBELLAR ATAXIA" (https://omim.org/entry/560000) - Orphanet: ORPHA:3390 (https://www.orpha.net/en/disease/detail/3390) - MONDO: MONDO:0010798 - MedGen/UMLS: UID 463309 / CUI C3151959 (https://www.ncbi.nlm.nih.gov/medgen/463309) - ICD-10/11: No dedicated code identified; would fall under mitochondrial disease / E88.4x-adjacent or N-codes for tubulopathy depending on coding system used (not independently confirmed in this search).

Synonyms: Renal tubulopathy, diabetes mellitus, and cerebellar ataxia; RTDMCA (informal).

Source of information: This entry is derived from a single aggregated case report of two affected siblings (not EHR-derived, not a registry) — i.e., disease-level literature description of an individual pedigree, not population-level epidemiology.

2. Etiology

Disease causal factor: A heteroplasmic, maternally transmitted partial duplication of the mitochondrial genome (~26 kb), consisting of one full-length mitochondrial genome plus one partially deleted genome, joined at a single abnormal junction located between the genes encoding ATP synthase subunit 6 (MT-ATP6) and cytochrome b (MT-CYB) [PMID:1531167]. Southern blot analysis demonstrated this rearrangement in the proband tissues; PCR of maternal lymphocyte DNA detected trace amounts of the same duplicated species, establishing maternal transmission — this was reported as "the first example of a maternally inherited duplication of the mitochondrial genome in man" [PMID:1531167].

Genetic risk factors: - Maternal carriage of the heteroplasmic mtDNA duplication (even at very low, PCR-detectable heteroplasmy levels in blood) is the sole documented risk factor. - As with other heteroplasmic mtDNA rearrangement disorders, the degree of heteroplasmy and its tissue distribution (mitotic segregation) likely determines phenotypic severity and tissue involvement, though this was not directly quantified across tissues in the original report. - No nuclear modifier genes have been described for this specific entity.

Environmental risk factors: None specifically reported for this syndrome. By extrapolation from mitochondrial disease biology generally, catabolic stress (intercurrent illness, fasting, dehydration) can precipitate metabolic decompensation in patients with underlying OXPHOS defects — consistent with the fact that both sisters in the index family had life-threatening deteriorations during episodes of diarrhea/vomiting/dehydration [PMID:1531167].

Protective factors: None identified in the literature search.

Gene-environment interactions: Not established for this entity specifically.

3. Phenotypes

The following phenotype list synthesizes the OMIM/MedGen/Orphanet-curated description, all traceable to the original 2-sibling report [PMID:1531167].

Renal / Metabolic (earliest-onset)

Endocrine

Neurological

Ophthalmologic

Dermatologic

Musculoskeletal / Neuromuscular

Auditory

Maternal carrier phenotype

The unaffected/mildly affected mother, who carried trace heteroplasmic levels of the duplication, exhibited ptosis, ophthalmoplegia, and muscle weakness [PMID:1531167] — a mild PEO-like phenotype consistent with low mutant load.

Severity/progression: Markedly severe and progressive; the older sister died of an acute dehydration episode at age 5, and the younger sister survived an early severe episode at age 3 but went on to accumulate ophthalmologic, retinal, and neurologic deficits. This indicates a severe, life-limiting, progressive multisystem course with a narrow window of survival through early decompensation events.

Quality of life impact: Not formally studied (no QOL instrument data identified); qualitatively, the disease is severely disabling and historically fatal in early-to-mid childhood based on the index cases.

4. Genetic/Molecular Information

Causal genetic lesion: Heteroplasmic mtDNA duplication (~26 kb), not a point mutation or single-gene nuclear variant. This is fundamentally different from most Mendelian dismech-style entries: the "gene" involved is the mitochondrial genome itself, with a single abnormal recombination/junction breakpoint located between MT-ATP6 (ATP synthase F0 subunit 6) and MT-CYB (cytochrome b, complex III core catalytic subunit) [PMID:1531167].

• Affected loci: MT-ATP6 (mitochondrially encoded, part of Complex V) and MT-CYB (mitochondrially encoded, catalytic core subunit of Complex III) flank the duplication junction. The duplication itself spans most of the mitochondrial genome (one full-length copy plus a partially-deleted copy).
• Variant classification: Not applicable in ACMG/AMP terms (structural mtDNA rearrangement, not a SNV); functionally analogous to a large structural mtDNA variant.
• Heteroplasmy: The duplication is heteroplasmic — present at high levels in affected tissue (muscle, presumably kidney) and at very low, PCR-only-detectable levels in maternal lymphocytes, consistent with mitotic/tissue segregation of heteroplasmy typical of mtDNA rearrangement disorders.
• Allele frequency in population databases: Not applicable — this is a private, family-specific structural mtDNA rearrangement, not a population polymorphism; not expected to appear in gnomAD/mtDNA reference sets.
• Somatic vs. germline origin: Germline (maternally transmitted), demonstrated by detection of the duplicated species in the mother's lymphocyte DNA — but note that mtDNA duplications/deletions can also arise de novo in oocytogenesis in many other reported cases of mtDNA rearrangement syndromes (general mtDNA-disease knowledge, not specific to this pedigree).
• Functional consequence: The duplication is associated with complex III (ubiquinol–cytochrome c oxidoreductase) deficiency, documented biochemically in skeletal muscle and lymphocytes from the second sister [PMID:1531167]. This represents impaired oxidative phosphorylation (OXPHOS) capacity.

Modifier genes/factors: None specifically described. General mtDNA-disease principle: heteroplasmy level and tissue-specific segregation are the major modifiers of phenotype in mtDNA rearrangement disorders (extrapolated, not shown directly for this family beyond the mother/daughters difference).

Epigenetic information: Not reported/applicable for this entity.

Chromosomal abnormalities: Not applicable (mitochondrial genome rearrangement, not nuclear chromosomal).

Relationship to other mtDNA rearrangement syndromes: This entity is nosologically related to the broader family of single large-scale mtDNA rearrangement syndromes (Kearns-Sayre syndrome, Pearson marrow-pancreas syndrome, chronic progressive external ophthalmoplegia/CPEO) — see GeneReviews "Single Large-Scale Mitochondrial DNA Deletion Syndromes" (NCBI Bookshelf NBK1203, last updated 2023). While deletions are the classic and usually sporadic lesion in that spectrum, duplications are less common, can be maternally inherited (unlike most single deletions, which are typically sporadic de novo events), and have been reported to co-occur with deletions in some patients. Renal tubulopathy, cerebellar ataxia, diabetes mellitus, and PEO/deafness are all recognized phenotypes across this broader mtDNA rearrangement spectrum (general mtDNA-rearrangement literature, e.g., Poulton et al., "Duplications of mitochondrial DNA: implications for pathogenesis," J Inherit Metab Dis 1992).

5. Environmental Information

No disease-specific environmental, occupational, or toxin exposures were identified as causal or modifying for this syndrome. Infectious/GI illness as a precipitant of acute decompensation is documented directly in the index cases (both sisters had severe deteriorations in the setting of diarrhea/vomiting/dehydration) [PMID:1531167] — this is best framed as a catabolic-stress trigger for acute metabolic crisis rather than a causal environmental factor, analogous to the general principle in mitochondrial and metabolic disease that intercurrent illness unmasks/worsens the underlying bioenergetic defect.

No infectious agents are causally implicated in the underlying disease process itself.

6. Mechanism / Pathophysiology

Causal chain (as supported by direct and extrapolated evidence):

1. Trigger/initiating lesion: Heteroplasmic mtDNA duplication (MT-ATP6/MT-CYB junction) inherited maternally or arising in oogenesis [PMID:1531167].
2. Molecular consequence: Disrupted assembly/function of the mitochondrial respiratory chain — specifically documented Complex III (ubiquinol-cytochrome c reductase) deficiency in muscle and lymphocytes [PMID:1531167]. (GO: mitochondrial respiratory chain complex III assembly, GO:0017062; GO: mitochondrial electron transport, ubiquinol to cytochrome c, GO:0006122)
3. Cellular consequence: Impaired oxidative phosphorylation → reduced ATP generation, particularly in tissues with high energetic demand and reliance on aerobic metabolism.
4. Tissue-level consequences (organ-specific downstream effects):
5. Proximal renal tubule (S3 segment): The proximal tubule performs highly energy-intensive active reabsorption of glucose, amino acids, low-molecular-weight proteins, and electrolytes; the S3 segment in particular cannot rely on anaerobic glycolysis due to relative paucity of glycolytic enzymes, making it exquisitely vulnerable to OXPHOS failure. This produces a generalized Fanconi-type proximal tubulopathy (glucosuria, aminoaciduria, phosphaturia, bicarbonaturia/acidosis, low-molecular-weight proteinuria, and, in this syndrome, wasting of potassium, sodium, calcium, and chloride). This mechanism is well established for mitochondrial cytopathies broadly (e.g., BCS1L-related complex III deficiency causing Fanconi syndrome, J Hum Genet 2021; complex I-related Fanconi syndrome, PMC3872385) and is consistent with, though not separately biochemically dissected at the renal tissue level in, the original report.
6. Pancreatic islet β-cells: High ATP-dependence for glucose-stimulated insulin secretion (via ATP-sensitive K+ channel closure) makes β-cells vulnerable to OXPHOS defects, producing progressive insulin-secretory failure and mitochondrial diabetes mellitus. This is the general mechanism invoked for mtDNA-related diabetes (e.g., m.3243A>G MIDD) and is extrapolated to this entity given the shared bioenergetic defect; not independently proven in this pedigree.
7. Cerebellum (Purkinje cells): Purkinje neurons show disproportionate vulnerability to OXPHOS/complex deficiency in primary mitochondrial disease, with selective Purkinje cell loss and OXPHOS protein deficiency documented in post-mortem mitochondrial-disease cerebellar tissue exceeding that in granule cells or dentate neurons (PMC12125081, 2025). This provides a plausible mechanistic basis for the progressive cerebellar ataxia in this syndrome, though again this is general mitochondrial-cerebellar-disease mechanism rather than tissue-specific data from the index family.
8. Retina (photoreceptors/RPE): High mitochondrial density and metabolic demand of photoreceptors underlies the pigmentary retinopathy and extinguished ERG.
9. Skeletal muscle: Ragged-red fibers on biopsy reflect subsarcolemmal mitochondrial proliferation, a classic histopathological marker of mtDNA rearrangement disease.
10. Skin: Pigmentary changes in photo-exposed areas — mechanism not detailed in the literature reviewed; possibly reflects generalized bioenergetic/oxidative stress effects on melanocytes, by analogy with other mitochondrial cytopathy skin phenotypes (J Am Acad Dermatol mtDNA syndromes review).

11. Bone: Osteoporosis/rickets likely multifactorial — secondary renal phosphate/calcium wasting (renal osteodystrophy-like mechanism) compounding any direct bioenergetic bone effect.

12. Systemic decompensation: Superimposed catabolic stress (GI illness, dehydration) in a patient with chronically compromised renal and systemic energy reserve precipitates acute, life-threatening metabolic crises — the proximate cause of death in the index family's older sibling.

Suggested ontology terms: - GO biological process: GO:0006122 (mitochondrial electron transport, ubiquinol to cytochrome c); GO:0042775 (mitochondrial ATP synthesis coupled electron transport); GO:0090207 (regulation of triglyceride metabolic process — n/a); more relevantly GO:0032543 (mitochondrial translation, if duplication affects gene dosage/translation). - Cell types (CL): CL:1000838 (kidney proximal straight tubule epithelial cell), CL:0000169 (type B pancreatic cell), CL:0000121 (Purkinje cell), CL:0000210 (photoreceptor cell), CL:0000187 (myocyte). - UBERON: UBERON:0004134 (renal proximal convoluted tubule)/UBERON:0004203 (proximal straight tubule), UBERON:0000006 (islet of Langerhans), UBERON:0002037 (cerebellum), UBERON:0000966 (retina). - GO cellular component: GO:0005750 (mitochondrial respiratory chain complex III), GO:0005743 (mitochondrial inner membrane).

Advanced/omics data: No transcriptomic, proteomic, metabolomic, single-cell, or spatial data specific to this syndrome were identified — consistent with its status as a single historically-reported family predating the omics era (report published 1992).

7. Anatomical Structures Affected

Organ level: - Primary: Kidney (proximal tubule), pancreas (endocrine), cerebellum, skeletal muscle, retina/eye, inner ear, skin, bone. - Body systems: Renal, endocrine, nervous (central — cerebellum; also cranial nerve/extraocular muscle involvement), musculoskeletal, integumentary, sensory (visual, auditory).

Tissue/cell level: - Renal proximal tubular epithelium (S1–S3 segments) - Pancreatic islet β-cells (endocrine) - Cerebellar Purkinje cells and associated cerebellar cortical neurons - Skeletal myofibers (ragged-red fiber pathology reflects subsarcolemmal mitochondrial accumulation) - Retinal photoreceptors/pigment epithelium - Cochlear/inner ear sensory epithelium (for hearing loss) - Epidermal melanocytes/keratinocytes (photo-exposed skin pigmentation)

Subcellular level: - Mitochondrial inner membrane respiratory chain complex III (GO:0005750) — primary biochemical lesion site - Mitochondrial matrix/genome (site of the duplication itself)

Localization/laterality: Systemic/bilateral, non-lateralized — consistent with a maternally-inherited mtDNA lesion affecting multiple organs simultaneously rather than a focal structural process.

8. Temporal Development

• Onset: Congenital/early infantile. Proximal tubulopathy manifests in the first year of life [PMID:1531167] — the earliest and defining presenting feature.
• Onset pattern: Insidious renal onset (failure to thrive, polyuria) followed by an accumulating, progressive multisystem course through childhood.
• Progression: Progressive and severe. Skin changes, cerebellar ataxia, myopathy, deafness, retinopathy, and diabetes mellitus accrue sequentially "during childhood" per the OMIM/MedGen synthesis.
• Disease course pattern: Chronic-progressive with acute, potentially fatal decompensation episodes superimposed (triggered by intercurrent GI illness/dehydration) — the older sister died during such an episode at age 5; the younger sister survived a similar episode at age 3 but continued to accrue chronic multisystem deficits afterward.
• Critical periods: Infancy (first year of life) represents the critical window for renal disease onset; early childhood (ages 3–5) represents a period of high mortality risk from acute metabolic/dehydration crises.
• Remission: No spontaneous or treatment-induced remission described; this is a progressive, non-remitting mitochondrial disease.

9. Inheritance and Population

Epidemiology: No formal prevalence or incidence estimates exist. This is described in the literature as based on a single reported family (two affected sisters), making it one of the rarest entities in the mitochondrial-disease nosology — effectively a "cases in literature" count of 2 (plus a mildly-affected obligate carrier mother). Orphanet classifies it as an ultra-rare disorder.

Inheritance pattern: Maternal (mitochondrial) inheritance, heteroplasmic — the duplication was detectable at trace levels in the unaffected/mildly-affected mother's lymphocyte DNA by PCR, establishing maternal transmission of the lesion [PMID:1531167]. This is distinct from the typical single mtDNA deletion syndrome pattern (Kearns-Sayre/Pearson), where deletions are usually sporadic, de novo events not transmitted from an affected mother; duplications, by contrast, have a documented capacity for maternal transmission (Poulton et al., 1992; general mtDNA rearrangement literature).

Penetrance/expressivity: Markedly variable expressivity is evident even within this single family — the mother, carrying very low-level heteroplasmy, manifested only a mild PEO-like phenotype (ptosis, ophthalmoplegia, muscle weakness), while her daughters (presumably with much higher heteroplasmic mutant load in affected tissues due to mitotic segregation during development) manifested the full severe multisystem syndrome. This is consistent with the general mitochondrial genetics principle of a heteroplasmy threshold effect for phenotypic expression.

Genetic anticipation: Not established, though the pattern of a mildly-affected mother and severely-affected offspring is at least superficially consistent with increasing heteroplasmic load through the maternal germline — this is not proven mechanistically in the report and should not be over-interpreted as "anticipation" in the classical repeat-expansion sense.

Germline mosaicism: The mother's low-level heteroplasmy detected only by PCR (not Southern blot) in lymphocytes is itself an example of germline/somatic mosaicism for the mtDNA rearrangement.

Founder effects / consanguinity / carrier frequency: Not applicable/not reported — as a private familial mtDNA rearrangement, there is no population carrier frequency, and consanguinity is not relevant to mitochondrial (non-Mendelian nuclear) inheritance.

Population demographics: No data on affected ethnic/geographic groups, sex ratio (both reported cases are female, consistent with maternal transmission being observed in daughters, though sons can also inherit maternal mtDNA), or age distribution beyond the index family (onset in first year of life; death/major morbidity by age 3–5 years in the reported cases).

10. Diagnostics

Laboratory tests: - Renal tubular function panel: serum and urine electrolytes (Na, K, Cl, Ca), evaluation for generalized Fanconi-type proximal tubulopathy (glucosuria, aminoaciduria, phosphaturia, bicarbonate wasting/acidosis, low-molecular-weight proteinuria) — LOINC panels for comprehensive metabolic panel and urine amino acid/protein screening apply generally (not disease-specific LOINC identified). - Blood glucose / HbA1c for diabetes mellitus monitoring. - Serum/CSF lactate and lactate:pyruvate ratio — a standard mitochondrial-disease screening test (not explicitly reported as measured in the original paper per the available excerpts, but standard of care for suspected mitochondrial cytopathy).

Biomarkers: No specific circulating biomarker beyond standard mitochondrial disease panel (lactate, pyruvate) was identified for this syndrome specifically.

Muscle biopsy / histopathology: Modified Gomori trichrome stain demonstrating ragged-red fibers — the classic morphological hallmark of mtDNA rearrangement disease, documented in this family [PMID:1531167].

Biochemical (enzymatic) testing: Mitochondrial respiratory chain enzyme assay on skeletal muscle and lymphocyte homogenates demonstrating isolated/predominant Complex III deficiency [PMID:1531167]. This is the key biochemical diagnostic finding.

Genetic testing: - Southern blot analysis of muscle mtDNA — the method used to first identify the ~26 kb heteroplasmic partial duplication with the ATP6/CYB junction [PMID:1531167]. This remains the gold-standard method for detecting large-scale mtDNA duplications/deletions (as opposed to standard long-range PCR, which can sometimes miss duplications or misinterpret them as deletions). - PCR amplification of the specific junction fragment — used to detect trace-level heteroplasmy in maternal lymphocyte DNA, establishing maternal transmission [PMID:1531167]. - Modern equivalent: whole mitochondrial genome sequencing with long-read or targeted long-range PCR approaches, capable of resolving duplication vs. deletion topology, would be the contemporary diagnostic approach (general mtDNA-diagnostics knowledge; not applied in the original 1992 report which pre-dates these methods). - Because mtDNA rearrangements can be tissue-restricted and heteroplasmy level–dependent, testing of an affected/high-heteroplasmy tissue (muscle) is preferred over blood for diagnostic sensitivity — consistent with GeneReviews guidance for single large-scale mtDNA deletion/duplication syndromes generally (NBK1203).

Ophthalmologic evaluation: Electroretinogram (documented as extinguished in the second sister) and fundoscopic exam for pigmentary retinopathy.

Audiology: Formal audiometric testing for sensorineural hearing loss.

Differential diagnosis: Other single large-scale mtDNA deletion/duplication syndromes (Kearns-Sayre syndrome, Pearson marrow-pancreas syndrome, CPEO/CPEO-plus); other primary mitochondrial disorders causing Fanconi syndrome (e.g., BCS1L-related complex III deficiency with Fanconi syndrome and GRACILE-spectrum disease, EHHADH- and GATM-related isolated renal Fanconi syndromes, RRM2B-related mtDNA depletion syndrome with encephalomyopathy and renal tubulopathy); other syndromic causes of diabetes + deafness + neurodegeneration (e.g., Wolfram syndrome, though that is autosomal recessive nuclear disease with diabetes insipidus rather than tubulopathy); mitochondrial diabetes and deafness (MIDD, typically m.3243A>G point mutation) as a distinguishing comparator — MIDD lacks the severe infantile Fanconi tubulopathy that defines this entity.

Screening: No population screening program exists for this ultra-rare entity; family-based cascade testing (maternal lineage) would be the logical approach given the demonstrated maternal transmission in the index pedigree.

11. Outcome/Prognosis

Survival/mortality: Severe. In the only reported family, the older sister died at age 5 of an acute episode of diarrhea, vomiting, and dehydration [PMID:1531167] — i.e., the disease was fatal in early childhood in this case. The younger sister survived a comparable severe dehydration episode at age 3 but continued to develop progressive multisystem disease (ophthalmoplegia, ptosis, retinal degeneration with extinguished ERG) thereafter. No formal survival statistics (5-year/10-year rates) exist given the extremely small reported case number.

Morbidity: Severe and multi-domain — progressive renal, neurological (cerebellar and cranial-nerve/extraocular), visual, auditory, endocrine (diabetes), musculoskeletal, and dermatological morbidity accrue over the disease course.

Complications: Acute life-threatening dehydration/electrolyte crises (directly tied to the severe renal salt-wasting tubulopathy) represent the dominant acute complication and cause of mortality in the index family. Chronic complications include blindness (from pigmentary retinopathy), deafness, cerebellar ataxia-related disability, osteoporosis/fracture risk, and the long-term complications of diabetes mellitus if the patient survives long enough to accrue them.

Prognostic factors: By analogy with other heteroplasmic mtDNA disorders, tissue-specific heteroplasmy level is likely the principal driver of phenotypic severity and prognosis (illustrated by the marked difference between the mildly-affected carrier mother and her severely-affected daughters), though this was not directly quantified across tissues in the report.

12. Treatment

There is no disease-specific treatment or cure described for this syndrome in the literature identified; management is supportive and follows general principles for mitochondrial cytopathies and their organ-specific complications, extrapolated from broader mitochondrial-disease and mtDNA-rearrangement-syndrome management guidance (GeneReviews NBK1203; mitochondrial diabetes reviews):

• Renal tubulopathy / Fanconi syndrome: Electrolyte and fluid replacement (sodium, potassium, bicarbonate, calcium, phosphate supplementation as needed), close monitoring and aggressive management of intercurrent illness to prevent life-threatening dehydration (the documented cause of death/near-death in the index family). NCIT: Fluid/electrolyte therapy — NCIT:C15747 (Supportive Care) as a general category.
• Diabetes mellitus: Insulin therapy is typically required as mitochondrial diabetes tends to progress more rapidly to insulin-dependence than typical type 2 diabetes; metformin is generally avoided because of the risk of precipitating or worsening lactic acidosis in the setting of underlying OXPHOS impairment. SGLT2 inhibitors have been proposed as a preferred oral option in mitochondrial diabetes in more recent general reviews (Clinical Diabetes, 2019; general mitochondrial-diabetes management literature — not specific trial data for this entity). NCIT:C15986 (Pharmacotherapy) with therapeutic_agent insulin (CHEBI or NCIT term) and, if used, SGLT2 inhibitor class.
• Mitochondrial "cocktail" / cofactor therapies: Coenzyme Q10, riboflavin, L-carnitine, and other mitochondrial cofactor supplements are used empirically in mitochondrial disease broadly, though efficacy remains unproven/experimental and no data exist specific to this syndrome. NCIT:C15433 (Nutritional Support) is the closest general term but per project convention should be scrutinized rather than mechanically applied.
• Ophthalmologic/audiological support: Low-vision aids, hearing aids/cochlear implant evaluation as needed for progressive sensory loss.
• Neurological/rehabilitative support: Physical/occupational therapy for cerebellar ataxia-related motor impairment (NCIT:C15302 Physical Therapy).
• Bone health: Vitamin D/calcium supplementation and monitoring for osteoporosis/rickets, particularly given renal phosphate/calcium wasting.
• Genetic counseling: Given demonstrated maternal transmission, genetic counseling of maternal relatives regarding recurrence risk (heteroplasmy-dependent and unpredictable, as for other heteroplasmic mtDNA disorders) is indicated. NCIT:C15240 (Genetic Counseling).

Experimental treatments: No clinical trials specific to this syndrome were identified on searches; general mitochondrial disease trials (e.g., of elamipretide, idebenone, or other mitochondrial-targeted agents) would not have specific evidence in this ultra-rare entity.

13. Prevention

No disease-specific primary prevention exists, given the sporadic/private nature of the causal mtDNA rearrangement (arising either de novo in oogenesis or, as shown here, transmitted at low heteroplasmy from a mildly-affected mother).

• Secondary prevention: Early recognition of infantile proximal tubulopathy with prompt electrolyte correction and aggressive management of intercurrent GI illness/dehydration could plausibly reduce acute mortality risk, based directly on the fatal decompensation event in the index case.
• Reproductive/genetic counseling: For families with a documented maternal mtDNA rearrangement, reproductive options analogous to those used for other heteroplasmic mtDNA disorders (prenatal testing, though heteroplasmy-based recurrence risk prediction is notoriously difficult for mtDNA disorders due to the mitotic bottleneck; mitochondrial replacement therapy in principle, though not reported as applied to this specific entity) would be the theoretical prevention avenues, extrapolated from general mitochondrial-genetics counseling practice (GeneReviews NBK1203 discusses this for the broader mtDNA rearrangement syndrome category).
• No vaccination, screening program, or public-health intervention is applicable to this private familial mtDNA disorder.

14. Other Species / Natural Disease

No naturally occurring animal model or veterinary case of this specific mtDNA duplication/phenotype combination was identified in this search. Mitochondrial DNA rearrangement disorders in general are not well-modeled by natural disease in other species (mtDNA rearrangements are typically studied via patient-derived cybrid/transmitochondrial cell lines rather than whole-animal natural disease models), and no OMIA entry or comparable veterinary literature was found for this entity.

15. Model Organisms

No dedicated animal or cellular model (transgenic mouse, cybrid cell line, iPSC-derived model) specific to this mtDNA duplication was identified in the literature searched. General mtDNA rearrangement research has used transmitochondrial cybrid cell lines (patient-derived mitochondria fused into mtDNA-depleted (ρ0) recipient cells) to study duplicated/rearranged mtDNA maintenance and segregation (Molecular Biology of the Cell, 2000, "Maintenance of Human Rearranged Mitochondrial DNAs in Long-Term Cultured Transmitochondrial Cell Lines") — this is a general methodology applicable to, but not specifically reported for, this syndrome's causal duplication. No knockout/knock-in mouse model, zebrafish model, or other organism-based model of this specific ATP6/CYB-junction duplication was identified.

Summary of Key Evidentiary Gaps

1. Single-family disease: All specific clinical/genetic findings trace to one 1992 report of two sisters and their mother [PMID:1531167]. No independent replication or additional families have been published in the searched literature.
2. No modern molecular characterization: The causal lesion was characterized by Southern blot and PCR in 1992; no subsequent whole-mtDNA sequencing, long-read confirmation, or updated molecular nomenclature (e.g., formal MITOMAP entry) was located.
3. No tissue-specific pathophysiology data: Kidney, pancreatic, and cerebellar tissue-level respiratory chain/heteroplasmy data were not directly reported (only muscle and lymphocyte); organ-specific mechanism discussion above is extrapolated from general mitochondrial-disease biology, not this entity specifically.
4. No treatment outcome data: No treatment trial, cohort, or even a second case report describing therapeutic approach/response was identified.

Recommendation for KB curation: Given the extreme rarity and single-source nature of this entry, evidence items should be conservatively scoped to what is directly stated in PMID:1531167 (and the OMIM/Orphanet/MedGen curated summaries derived from it), with any mechanism-level extrapolation (e.g., proximal tubule bioenergetics, β-cell ATP-dependent insulin secretion, Purkinje cell vulnerability) clearly flagged via appropriate evidence_source classification (e.g., citing general mitochondrial-disease mechanism papers separately from the disease-specific case report) rather than implied as directly demonstrated in this pedigree.

Sources

• Maternally inherited duplication of the mitochondrial genome in a syndrome of proximal tubulopathy, diabetes mellitus, and cerebellar ataxia - PMC (PMID:1531167)
• Maternally inherited duplication... - PubMed
• OMIM #560000 - RENAL TUBULOPATHY, DIABETES MELLITUS, AND CEREBELLAR ATAXIA
• Orphanet: Proximal tubulopathy-diabetes mellitus-cerebellar ataxia syndrome (ORPHA:3390)
• Proximal tubulopathy-diabetes mellitus-cerebellar ataxia syndrome - MedGen - NCBI (C3151959)
• Renal tubulopathy-diabetes mellitus-cerebellar ataxia - wikidoc
• About: Proximal tubulopathy-diabetes mellitus-cerebellar ataxia syndrome - NCSU rare diseases
• Single Large-Scale Mitochondrial DNA Deletion Syndromes - GeneReviews (NBK1203)
• Duplications of mitochondrial DNA: Implications for pathogenesis - Poulton, J Inherit Metab Dis 1992
• BCS1L mutations produce Fanconi syndrome with developmental disability - J Hum Genet 2021
• Distinct Mitochondrial Pathologies Caused by Mutations of the Proximal Tubular Enzymes EHHADH and GATM - PMC8326905
• Renal Fanconi Syndrome Is Caused by a Mistargeting-Based Mitochondriopathy - ScienceDirect
• Mitochondrial Diabetes: More Than Just Hyperglycemia - Clinical Diabetes, ADA
• Management of mitochondrial diabetes in the era of novel therapies - ScienceDirect
• Delineating the mechanisms of cerebellar degeneration in paediatric and adult primary mitochondrial disease - PMC12125081
• RRM2B-related mitochondrial DNA depletion syndrome, encephalomyopathic form with renal tubulopathy - MedlinePlus Genetics
• Mitochondrial DNA deletion and duplication in Kearns–Sayre Syndrome with initial presentation as Pearson Marrow-Pancreas Syndrome - PMC7667363

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.